Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria M Richon

Showing results (11-20 of 54) with videos related to

Pageof 6
Sort By:
Advances in Cancer Research|August 26, 2004
Histone deacetylase inhibitorsPaul A Marks, Victoria M Richon, Thomas Miller, et al.
Novartis Foundation Symposium|June 3, 2004
Histone deacetylase inhibitors: development as cancer therapyPaul A Marks, Victoria M Richon, Wm Kevin Kelly, et al.
Molecular Cancer Therapeutics|August 25, 2006
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX fociAnupama Munshi, Toshimitsu Tanaka, Marvette L Hobbs, et al.
International Journal of Toxicology|November 12, 2009
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostatJanet S Kerr, Sheila Galloway, Armando Lagrutta, et al.
Anticancer Research|August 10, 2002
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumorsLeonard A Cohen, Paul A Marks, Richard A Rifkind, et al.
Blood|May 6, 2006
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlanca Sanchez-Gonzalez, Hui Yang, Carlos Bueso-Ramos, et al.
Methods in Enzymology|February 21, 2004
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivoVictoria M Richon, Xianbo Zhou, J Paul Secrist, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler, Xianbo Zhou, Wei-Sheng Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasChristopher J Sneeringer, Margaret Porter Scott, Kevin W Kuntz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acidChristopher M Reilly, Nilamadhab Mishra, Julie M Miller, et al.
Pageof 6

Showing results (11-20 of 54) with videos related to

Sort By:
Pageof 6
Advances in Cancer Research|August 26, 2004
Histone deacetylase inhibitorsPaul A Marks, Victoria M Richon, Thomas Miller, et al.
Novartis Foundation Symposium|June 3, 2004
Histone deacetylase inhibitors: development as cancer therapyPaul A Marks, Victoria M Richon, Wm Kevin Kelly, et al.
Molecular Cancer Therapeutics|August 25, 2006
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX fociAnupama Munshi, Toshimitsu Tanaka, Marvette L Hobbs, et al.
International Journal of Toxicology|November 12, 2009
Nonclinical safety assessment of the histone deacetylase inhibitor vorinostatJanet S Kerr, Sheila Galloway, Armando Lagrutta, et al.
Anticancer Research|August 10, 2002
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumorsLeonard A Cohen, Paul A Marks, Richard A Rifkind, et al.
Blood|May 6, 2006
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlanca Sanchez-Gonzalez, Hui Yang, Carlos Bueso-Ramos, et al.
Methods in Enzymology|February 21, 2004
Histone deacetylase inhibitors: assays to assess effectiveness in vitro and in vivoVictoria M Richon, Xianbo Zhou, J Paul Secrist, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler, Xianbo Zhou, Wei-Sheng Xu, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 17, 2010
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomasChristopher J Sneeringer, Margaret Porter Scott, Kevin W Kuntz, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2004
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acidChristopher M Reilly, Nilamadhab Mishra, Julie M Miller, et al.
Pageof 6